# Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma

> **NCT04260191** · PHASE1 · TERMINATED · sponsor: **Amgen** · enrollment: 15 (actual)

## Conditions studied

- Gastric and Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** AMG 910

## Key facts

- **NCT ID:** NCT04260191
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-06-29
- **Primary completion:** 2022-06-02
- **Final completion:** 2022-06-02
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Business Decision
- **Last updated:** 2024-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04260191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04260191, "Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT04260191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*